Decentralized Clinical Trials in India: What DCTs Are, Where CDSCO Stands, and the Skills They Demand

A patient in a tier-two town enrols in a Phase III trial. The investigational drug arrives at her door in a temperature-controlled shipment. A trained nurse visits her home to draw blood, which goes to a local accredited lab. Her follow-up consultations happen over video with the investigator at a hospital 300 kilometres away. A wearable on her wrist streams heart rate and activity data continuously. She reports side effects through an app on her phone.

That description is not science fiction, and it is not a fully hypothetical trial. Elements of it are running in studies in India right now, usually as part of hybrid designs attached to global multi-regional trials. This is what people mean by decentralized clinical trials, and it is one of the more consequential shifts in how studies are actually run. It is also an area where India’s regulatory framework is visibly still catching up to operational practice.

For anyone building a clinical research or data management career, understanding DCTs matters for a practical reason: the sponsors and large CROs that hire aggressively are the ones adopting these models fastest, and the skill gap between traditional site monitoring and decentralized trial operations is real.

What a decentralized clinical trial actually is

A decentralized clinical trial moves some or all study activities away from the traditional investigator site and toward the participant. Rather than requiring a patient to travel to a hospital for every visit, assessment, and consent signature, a DCT distributes those activities across settings the patient can reach more easily, including their own home.

In practice, very few trials are fully decentralized. The dominant model is the hybrid trial, which keeps a physical investigator site but shifts specific activities to remote or local delivery. The building blocks are worth knowing individually, because a given protocol will use some and not others.

Electronic informed consent (eConsent). Consent presented and documented through a validated digital platform, sometimes with interactive or multimedia explanations, rather than only a paper form. The ethical requirements do not change. The medium does.

Telemedicine and remote visits. Follow-up consultations, some assessments, and adverse event discussions conducted by video rather than in person, where the protocol and the assessment allow it.

Direct-to-patient (DTP) supply. Investigational product shipped directly to the participant’s home under appropriate temperature control and chain-of-custody documentation, instead of dispensed only at the site pharmacy.

Home health services. Trained nurses or phlebotomists visiting the participant’s home for blood draws, injections, vital signs, or other procedures that do not require hospital infrastructure.

Local labs and imaging. Using accredited facilities near the participant rather than routing everything through the site, which widens the geographic pool of eligible participants.

Wearables and connected devices. Continuous or high-frequency data capture from sensors: heart rate, glucose, activity, sleep, and more. This produces far more data points than periodic clinic measurements.

Electronic patient-reported outcomes (ePRO). Symptom diaries, quality-of-life instruments, and outcome questionnaires completed by the patient on an app or provided device.

Remote and risk-based monitoring. Instead of a CRA travelling to every site to verify every data point, monitoring shifts toward centralised statistical review of incoming data plus targeted, remote, or reduced on-site verification.

Why decentralized trials matter

The case for DCTs is not novelty. It is recruitment, retention, and reach, which are the three problems that most often slow or sink a trial.

Recruitment improves because eligibility is no longer tied to living near a specialist site. A trial that can accept participants from smaller towns and rural areas, with home visits and local labs handling the logistics, draws from a much larger pool. For India specifically, where research-active hospitals cluster in a handful of metros, this geographic widening is significant.

Retention improves because the participant burden drops. Dropout is often driven by the sheer inconvenience of repeated hospital travel, time off work, and long waits. When some visits happen at home or over video, more participants stay enrolled through the full protocol.

Data richness improves with wearables and ePRO. Continuous physiological data and frequent patient-reported symptom capture give a far more complete picture than a reading taken once every few weeks in a clinic, where the artificial setting can itself distort the measurement.

There is also a diversity argument. Trials that only recruit from major urban tertiary centres tend to enrol a narrow slice of the population. Decentralized elements make it easier to include participants who could never realistically commit to frequent site visits, which matters for how well trial results generalise.

None of this removes the need for rigour. If anything, decentralized designs raise the bar on data integrity, oversight, and logistics, because there are more moving parts and more points at which data can be captured incorrectly or supply chains can break.

Where India and CDSCO stand as of 2026

This is the part that requires care, because it is easy to overstate. As of 2026, India does not have a dedicated regulation that defines, authorises, or sets standards for decentralized clinical trials as a category. The governing framework remains the New Drugs and Clinical Trials Rules 2019, and those rules are built around the conventional model of an investigator, a defined trial site, and an ethics committee overseeing that site.

That does not mean DCT elements are prohibited. It means they operate inside a framework that was not written with them in mind, so their acceptability is assessed element by element, and practice is cautious.

A few specific points are worth stating accurately:

Telemedicine has a clearer basis than most DCT elements. The Telemedicine Practice Guidelines issued in 2020 gave registered medical practitioners in India a recognised framework for remote consultation. This provides a foundation for telemedicine visits within trials, though the guidelines were written for general clinical practice rather than trial conduct specifically.

eConsent sits in an unsettled area. India has a long-standing requirement, dating to notifications from the 2010s, for audio-visual recording of the informed consent process in certain trial categories, including trials of new chemical entities and those involving vulnerable participants. That requirement was designed around an in-person process. There is no comprehensive CDSCO circular as of 2026 that defines standards for fully electronic consent in trials. Some sponsors use electronic consent tools within hybrid designs where an investigator or delegate still conducts and documents the consent discussion, but ethics committees differ in how they treat this, and the practice is not uniform.

Data protection is now a live consideration. The Digital Personal Data Protection Act 2023 introduced a formal data protection regime in India. Its rules and enforcement mechanics were still being operationalised through this period. Trial sponsors handling participant data through apps, wearables, and remote platforms have to account for this framework, and the question of where and how trial data is stored and transferred is more prominent than it was a few years ago. Anyone claiming settled certainty on cross-border trial data flows under Indian law in 2026 is overstating the position.

International guidance is moving faster than Indian regulation. ICH E6(R3), finalised in 2023 and implemented by major regulators through 2024, is the first ICH GCP revision to explicitly accommodate decentralized elements and remote monitoring. Global sponsors running trials in India apply E6(R3) operationally because their protocols require it. CDSCO has not issued a formal circular adopting E6(R3) as the binding national standard as of 2026, though draft GCP guidance circulated in 2025 reflected several of its concepts.

The honest summary: India is running hybrid decentralized trials in practice, led by global sponsors and large CROs, while the domestic regulatory framework has not yet formalised most of the category. The direction of travel is clear, but the specifics are still being worked out, and professionals should treat any strong claim about “CDSCO-approved DCTs” with scepticism.

Hybrid versus fully decentralized

It helps to hold two categories apart, because they carry very different regulatory and operational weight in India.

Feature	Traditional site trial	Hybrid DCT	Fully decentralized
Physical investigator site	Central to everything	Retained, reduced role	Minimal or none
Most visits	On-site	Mix of on-site, home, remote	Remote and home
Consent	In-person, paper	In-person or supported eConsent	eConsent
Drug supply	Site pharmacy	Site or direct-to-patient	Direct-to-patient
Monitoring	On-site SDV	Remote and risk-based	Largely remote
Common in India (2026)	Yes, standard	Emerging, sponsor-led	Rare

For the Indian context specifically, the hybrid column is where the real activity is. Fully decentralized trials that dispense with a physical investigator site face too many open regulatory questions to be common practice here yet. When a job description or a sponsor talks about DCTs in India in 2026, they almost always mean hybrid designs.

The skills CRAs need for decentralized trials

The monitoring role changes meaningfully in a decentralized context, and this is where a genuine skills gap sits between CRAs trained only on conventional on-site work and what sponsors now want.

Remote and risk-based monitoring. The single most important shift. Instead of travelling to a site to verify every data point, CRAs conduct centralised review of incoming data, remote source data verification through secured access, and targeted on-site visits driven by risk signals rather than a fixed schedule. Reading a monitoring dashboard, interpreting key risk indicators, and deciding where physical verification is actually needed are now core competencies.

Oversight of remote and home-based activities. A CRA now has to assure the quality of activities they did not personally witness: home nursing visits, local lab handling, direct-to-patient shipments. That means verifying documentation, chain-of-custody records, and delegation logs for staff who may never set foot in the investigator site.

eConsent verification. Where electronic consent is used, the CRA checks consent audit trails, version control on consent documents, timestamps, and evidence that the consent discussion actually occurred, including any required audio-visual documentation.

Data integrity for electronic sources. ePRO submissions and wearable data have to meet the same ALCOA+ standards (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available) as any other trial data. A CRA needs to understand how these principles apply to device-generated and patient-entered data, where the failure modes are different from paper records.

For anyone building toward this work, the clinical research associate career path starts from monitoring fundamentals, and the remote and risk-based skills sit on top of that foundation rather than replacing it.

The impact on clinical data management

Decentralized trials are, at their core, a data problem. They multiply the number of sources feeding into the study and change the shape of the data coming in.

A conventional trial’s data arrives in fairly predictable structured forms from a central set of sites. A decentralized trial adds continuous wearable streams, high-frequency ePRO submissions, telemedicine visit records, and results from local labs scattered across the country rather than a single central lab. Each source has its own format, its own timing, and its own quality quirks.

The data manager’s work expands accordingly. Integrating device data into the EDC, defining edit checks that make sense for high-frequency data, reconciling patient-entered data against clinical records, and handling the missing-data patterns typical of app-based capture all become part of the job. Patient-reported and device data also carry quality issues that site-entered data does not, such as participants filling in diaries retrospectively or wearables producing artefacts during charging or removal.

These are learnable, structured skills, and they build directly on core data management competence: EDC platform familiarity, data validation logic, query management, and reconciliation. iLearn CRI’s Clinical Data Management course (3 months, ₹40,000) covers the EDC and data-handling foundations that this expanded, multi-source environment depends on. Decentralized designs raise the ceiling on what a strong data manager can contribute; they do not change the fundamentals underneath.

What to take from this

Decentralized clinical trials are not a marketing label. They are a real and growing way of running studies, driven by hard problems in recruitment, retention, and reach. In India as of 2026, the practical reality is hybrid designs led by global sponsors and large CROs, running inside a regulatory framework that has not yet formally defined the category. eConsent, data protection, and full decentralization all sit in areas where Indian guidance is still evolving, and it pays to be precise rather than to assume more regulatory clarity than exists.

For CRAs and data managers, the takeaway is straightforward. The employers moving fastest on decentralized and risk-based trial models are the ones with the most opportunities. Building remote monitoring competence, understanding electronic data sources, and knowing how these designs actually work is a concrete way to be more useful to those employers, well before the domestic regulations fully catch up.